Short Interest in Femasys Inc. (NASDAQ:FEMY) Declines By 39.0%

Femasys Inc. (NASDAQ:FEMY) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 144,700 shares, a decrease of 39.0% from the January 15th total of 237,300 shares. Based on an average trading volume of 192,200 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on FEMY. Chardan Capital cut their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Femasys in a research note on Tuesday, February 11th.

Institutional Investors Weigh In On Femasys

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the last quarter. Aljian Capital Management LLC purchased a new stake in shares of Femasys in the third quarter valued at about $27,000. XTX Topco Ltd increased its stake in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Jane Street Group LLC purchased a new position in Femasys during the fourth quarter worth about $30,000. Finally, Northern Trust Corp lifted its position in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after purchasing an additional 37,675 shares during the period. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Stock Up 15.2 %

Femasys stock opened at $1.59 on Friday. The stock has a 50 day moving average of $1.15 and a two-hundred day moving average of $1.13. Femasys has a twelve month low of $0.86 and a twelve month high of $2.40. The stock has a market capitalization of $36.41 million, a price-to-earnings ratio of -1.96 and a beta of -2.81. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.